HoldingsChannel.com
Esperion Therapeutics Inc (New) insider buying image
The table below summarizes the most recent Esperion Therapeutics Inc (New) insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Esperion Therapeutics Inc (New) insider buys are important for investors to follow.
DateInsiderPriceAmount
5-10-2023
Insider Buy		 Stephen Rocamboli
Director		 $1.50
CAGR » 		$12,125.94
8,111 shares
5-11-2023
Insider Buy		 J. Martin Carroll
Director		 $1.55
CAGR » 		$48,830.58
31,500 shares
5-9-2023
Insider Buy		 Sheldon L. Koenig
President and CEO		 $1.26
CAGR » 		$25,192.00
20,000 shares
8-31-2022
Insider Buy		 Eric Warren
Chief Commercial Officer		 $7.46
CAGR » 		$7,460.00
1,000 shares
6-2-2022
Insider Buy		 J. Martin Carroll
Director		 $5.64
CAGR » 		$28,179.50
5,000 shares
8-5-2022
Insider Buy		 Sheldon L. Koenig
President and CEO		 $5.80
CAGR » 		$49,950.08
8,606 shares
5-6-2021
Insider Buy		 Target N. V. Biotech
>10% Owner		 $20.21
CAGR » 		$4,648,482.00
230,000 shares
5-24-2021
Insider Buy		 Target N. V. Biotech
>10% Owner		 $20.22
CAGR » 		$2,021,620.00
100,000 shares
5-19-2021
Insider Buy		 Target N. V. Biotech
>10% Owner		 $20.37
CAGR » 		$4,073,960.00
200,000 shares
5-6-2021
Insider Buy		 Target N. V. Biotech
>10% Owner		 $20.21
CAGR » 		$4,648,482.00
230,000 shares
11-3-2020
Insider Buy		 Target N. V. Biotech
>10% Owner		 $25.31
CAGR » 		$5,062,120.00
200,000 shares
3-11-2020
Insider Buy		 Timothy M. Mayleben
President & CEO		 $43.00
CAGR » 		$107,500.00
2,500 shares
2-28-2020
Insider Buy		 Timothy M. Mayleben
President & CEO		 $49.00
CAGR » 		$245,000.00
5,000 shares
1-23-2020
Insider Buy		 Target N. V. Biotech
>10% Owner		 $52.12
CAGR » 		$1,042,398.00
20,000 shares
11-6-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $36.98
CAGR » 		$184,900.00
5,000 shares
11-6-2019
Insider Buy		 Target N. V. Biotech
>10% Owner		 $37.30
CAGR » 		$2,797,560.00
75,000 shares
9-6-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $34.55
CAGR » 		$259,106.60
7,500 shares
9-4-2019
Insider Buy		 Target N. V. Biotech
>10% Owner		 $33.78
CAGR » 		$2,702,208.00
80,000 shares
8-1-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $39.56
CAGR » 		$197,800.00
5,000 shares
7-23-2019
Insider Buy		 Target N. V. Biotech
>10% Owner		 $42.65
CAGR » 		$2,132,565.00
50,000 shares
6-28-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $46.00
CAGR » 		$230,000.00
5,000 shares
3-29-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $40.00
CAGR » 		$200,000.00
5,000 shares
3-20-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $43.48
CAGR » 		$217,400.00
5,000 shares
3-14-2019
Insider Buy		 Timothy M. Mayleben
President & CEO		 $48.73
CAGR » 		$243,650.00
5,000 shares
3-14-2019
Insider Buy		 Target N. V. Biotech
>10% Owner		 $49.89
CAGR » 		$2,494,355.00
50,000 shares
1-4-2019
Insider Buy		 Target N. V. Biotech
>10% Owner		 $41.29
CAGR » 		$3,303,256.00
80,000 shares
12-24-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $39.91
CAGR » 		$1,995,725.00
50,000 shares
12-17-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $47.73
CAGR » 		$2,864,070.00
60,000 shares
8-3-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $46.14
CAGR » 		$2,306,970.00
50,000 shares
7-12-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $41.77
CAGR » 		$2,088,300.00
50,000 shares
6-29-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $39.48
CAGR » 		$1,973,805.00
50,000 shares
6-21-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $38.57
CAGR » 		$2,314,224.00
60,000 shares
6-7-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $37.79
CAGR » 		$2,267,292.00
60,000 shares
6-5-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $38.47
CAGR » 		$2,308,440.00
60,000 shares
5-21-2018
Insider Buy		 Target N. V. Biotech
>10% Owner		 $40.11
CAGR » 		$5,213,770.00
130,000 shares
3-21-2017
Insider Buy		 Gilbert S. Omenn
Director		 $42.26
CAGR » 		$42,260.00
1,000 shares
11-1-2016
Insider Buy		 Narendra D. Lalwani
Chief Operating Officer		 $9.93
CAGR » 		$49,650.00
5,000 shares
7-6-2016
Insider Buy		 Mark E. McGovern
Director		 $10.00
CAGR » 		$50,000.00
5,000 shares
5-4-2016
Insider Buy		 Timothy M. Mayleben
President & CEO		 $14.85
CAGR » 		$103,950.00
7,000 shares
3-1-2016
Insider Buy		 Gilbert S. Omenn
Director		 $15.28
CAGR » 		$76,400.00
5,000 shares
1-27-2016
Insider Buy		 Timothy M. Mayleben
President & CEO		 $15.88
CAGR » 		$57,168.00
3,600 shares
1-15-2016
Insider Buy		 Timothy M. Mayleben
President & CEO		 $14.08
CAGR » 		$101,376.00
7,200 shares
10-21-2014
Insider Buy		 Alta Partners VIII, L.P.
>10% Owner		 $20.00
CAGR » 		$10,000,000.00
500,000 shares
10-21-2014
Insider Buy		 Daniel Janney
Director and >10% Owner		 $20.00
CAGR » 		$10,000,000.00
500,000 shares
10-21-2014
Insider Buy		 Gilbert S. Omenn
Director		 $20.00
CAGR » 		$100,000.00
5,000 shares
10-21-2014
Insider Buy		 Parters Vii L. P. Domain
>10% Owner		 $20.00
CAGR » 		$10,000,000.00
500,000 shares
7-1-2013
Insider Buy		 Brian H. Dovey
>10% Owner		 $14.00
CAGR » 		$3,999,996.00
285,714 shares
7-1-2013
Insider Buy		 Brian K. Halak
>10% Owner		 $14.00
CAGR » 		$3,999,996.00
285,714 shares
7-1-2013
Insider Buy		 Parters Vii L. P. Domain
>10% Owner		 $14.00
CAGR » 		$3,932,922.00
280,923 shares
7-1-2013
Insider Buy		 Vii Associates LP DP
>10% Owner		 $14.00
CAGR » 		$67,074.00
4,791 shares
7-1-2013
Insider Buy		 James C. Blair
>10% Owner		 $14.00
CAGR » 		$3,999,996.00
285,714 shares
7-1-2013
Insider Buy		 Nicole Vitullo
Director and >10% Owner		 $14.00
CAGR » 		$3,999,996.00
285,714 shares
7-1-2013
Insider Buy		 Jesse I. Treu
>10% Owner		 $14.00
CAGR » 		$3,999,996.00
285,714 shares
7-1-2013
Insider Buy		 Kathleen K. Schoemaker
>10% Owner		 $14.00
CAGR » 		$3,999,996.00
285,714 shares
7-1-2013
Insider Buy		 Capital LP Aisling II
>10% Owner		 $14.00
CAGR » 		$3,333,666.00
238,119 shares
7-1-2013
Insider Buy		 Alta Partners VIII, L.P.
>10% Owner		 $14.00
CAGR » 		$3,299,996.00
235,714 shares
7-1-2013
Insider Buy		 Daniel Janney
Director		 $14.00
CAGR » 		$3,299,996.00
235,714 shares
7-1-2013
Insider Buy		 Patrick G. Enright
Director and >10% Owner		 $14.00
CAGR » 		$3,033,464.00
216,676 shares
7-1-2013
Insider Buy		 Dov A. Goldstein, M.D.
Director		 $14.00
CAGR » 		$3,333,666.00
238,119 shares
7-1-2013
Insider Buy		 Louis G. Lange
Director		 $14.00
CAGR » 		$198,996.00
14,214 shares
7-1-2013
Insider Buy		 Roger S. Newton
Executive Chairman, CSO		 $14.00
CAGR » 		$592,844.00
42,346 shares
7-1-2013
Insider Buy		 Timothy M. Mayleben
President and CEO		 $14.00
CAGR » 		$70,000.00
5,000 shares
7-1-2013
Insider Buy		 Longitude Capital Partners, LLC
>10% Owner		 $14.00
CAGR » 		$3,033,464.00
216,676 shares

Also See: Institutional Holders of ESPR
Also See: SEC filings

ESPR Performance Since Insider Purchase
Below we present the annualized performance delivered by Esperion Therapeutics Inc (New) stock since 5-10-2023 (the date of the most recent insider purchase). The performance of the investment from the time Esperion Therapeutics Inc (New) insider buying occurred is the ultimate test of whether insiders were right about ESPR being a good buy.

Growth of $10,000.00
Without Dividends Reinvested
Start date: 05/11/2023
End date: 04/22/2024
Start price/share: $1.49
End price/share: $1.91
Dividends collected/share: $0.00
Total return: 28.19%
Annualized Gain: 29.65%
Starting investment: $10,000.00
Ending investment: $12,819.00
Years: 0.95

Esperion Therapeutics Inc (New) Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Esperion Therapeutics Inc (New) insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding ESPR

ESPR — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree ESPR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

ESPR — Performance

Esperion Therapeutics Inc (New) Insider Buying | www.HoldingsChannel.com

Copyright © 2013 - 2024, All Rights Reserved Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.